The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry
Patient, or another authorized person as per country-specific regulations, is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements.
For Cohort 1, patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
For Cohort 2, patient is treated using a commercially available MicroVention mechanical thrombectomy device as the first-line treatment strategy and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
Patient is or is expected to be inaccessible for follow-up.
Patient is participating or intends to participate in another study that changes the site practice.
Patient is already participating in the MAESTRO study for the same pathology.
* Cohort 1: Patients with ruptured or unruptured intracranial aneurysms who are treated endovascularly with commercially available MicroVention implant devices at the direction of the treating physician * Cohort 2: Patients with acute ischemic stroke in the cerebral circulation who are treated with mechanical thrombectomy using selected commercially available Microvention devices, at the direction of the treating physician.
Cohort
Prospective
All Microvention Class III implantable device CE marked
DeviceEndovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
All Microvention Mechanical Thrombectomy Class III device CE marked
DeviceEndovascular treatment of acute ischemic stroke with commercially available MicroVention devices.
Cohort 1: Proportion of aneurysms with complete occlusion
based on Raymond-Roy occlusion classification (RROC) evaluated by an independent Core laboratory
Cohort 2: Proportion of patients achieving final mTICI ≥ 2b revascularization
based on independent Corelab assessment
Click on the lead sponsor to view all of their trials.
